MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -16,619 | -15,948 | 7,985 | 13,826 |
| Stock-based compensation | 6,455 | 6,972 | 4,318 | 12,905 |
| Interest on liability for sale of future royalties | 2,565 | 3,885 | 3,512 | 7,052 |
| Sold portion of royalty revenue | 3,275 | 3,356 | 3,332 | 6,123 |
| Write-off of inventory | 1,075 | 2,062 | 3,277 | 5,058 |
| Noncash lease expense of right-of-use assets | 532 | -603 | 740 | 1,075 |
| Depreciation and amortization | 6,382 | 6,030 | 2,061 | 4,193 |
| (gain) loss on foreign currency transactions | 1,318 | 3 | 120 | -7,872 |
| Impairment loss on available-for-sale investment | NaN | 0 | -6,409 | NaN |
| Net accretion of investments | -271 | -402 | -567 | -1,678 |
| Change in fair value of contingent liability | -2,777 | 1,029 | NaN | NaN |
| Amortization of debt discount and issuance costs | 452 | 478 | 158 | 218 |
| Loss on settlement of debt | -917 | NaN | NaN | NaN |
| Other, net | 62 | -155 | NaN | NaN |
| Change in deferred tax liability | NaN | -4,969 | NaN | NaN |
| Accounts receivable, net | -10,290 | -817 | -9,759 | 15,338 |
| Inventory | 14,928 | -797 | 1,758 | 5,663 |
| Prepaid expenses and other current assets | -6,557 | -2,328 | 6,989 | 5,371 |
| Other assets | 2,416 | 383 | 1 | 1,525 |
| Accounts payable | 7,110 | -17,188 | -2,988 | 3,465 |
| Accrued expenses and other current liabilities | -5,771 | 13,350 | -761 | -9,333 |
| Deferred revenue | -4,878 | -3,009 | 1,891 | -7,141 |
| Operating lease liabilities | -939 | 0 | 46 | -919 |
| Net cash used in operating activities | -5,365 | -7,958 | 23,640 | 2,573 |
| Purchase of available-for-sale securities | 10,301 | 13,723 | 55,953 | 88,127 |
| Proceeds from maturities of available-for-sale securities | 30,906 | 71,496 | 42,020 | 101,792 |
| Acquisition of scpharma, net of cash acquired | NaN | 347,742 | NaN | NaN |
| Issuance of note receivable | NaN | 0 | 10,000 | NaN |
| Purchase of property and equipment | 1,880 | 1,994 | 1,125 | 1,447 |
| Net cash provided by investing activities | 18,725 | -291,963 | -25,058 | 12,218 |
| Proceeds from term loan | NaN | 250,000 | 75,000 | NaN |
| Payment of loan issuance costs | NaN | 4,919 | 2,347 | NaN |
| Principal payments on senior convertible notes | 35,502 | NaN | NaN | NaN |
| Proceeds from market price stock purchase plan and employee stock purchase plan | NaN | 654 | 50 | 1,288 |
| Net proceeds related to issuance of common stock associated with restricted stock units and stock options | -105 | -1,874 | 743 | 4,393 |
| Principal payments on financing liability | 279 | 196 | 154 | 376 |
| Milestone payment | NaN | NaN | NaN | 639 |
| Milestone right agreement payment | NaN | 0 | 639 | NaN |
| Proceeds from market price stock purchase plan | 270 | NaN | NaN | NaN |
| Net cash (used in) provided by financing activities | -35,406 | 247,413 | 71,806 | -4,120 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -22,046 | -52,508 | 70,388 | 10,671 |
| Cash, cash equivalents and restricted cash, beginning of period | 75,627 | 128,135 | 47,076 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 53,581 | 75,627 | 128,135 | NaN |